Last update Nov. 3, 2024
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
リスデキサンフェタミンメシル酸塩 is Lisdexamfetamine Mesilate in Japanese.
Is written in other languages:リスデキサンフェタミンメシル酸塩 is also known as
リスデキサンフェタミンメシル酸塩 belongs to these groups or families:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A prodrug that is metabolized directly in the intestine to dextroamphetamine. It is used to treat Attention Deficit Hyperactivity Disorder (ADHD) and Binge eating disorder. Dextroamfetamine is a sympathomimetic drug, central nervous system stimulant, whose action and uses are similar to amphetamine (see information) which is its dextro isomer. Oral administration.
Dextroamfetamine is excreted in breast milk, concentrating about 3 times more than in plasma. This concentration assumes a relative dose about 6% (Ilett, 2007)
In infants whose mothers were taking dexamfetamine as treatment for ADHD, levels ranging from undetectable to 14% of maternal plasma levels have been measured and no problems were observed in the clinical and developmental follow-up of these infants (Benassayag 2024, Ilett, 2007).
There is little information on the impact of amphetamine abuse on the development and health of infants (Oei, 2012, Wise, 2007; Moretti, 2000), but it is known that they are more exposed to social problems, domestic violence, and lower breastfeeding rates. (Oei, 2010)
There is controversy over the possibly mild negative effect of amphetamine on prolactin (Petraglia, 1987; DeLeo, 1983), but milk production in mothers who took it therapeutically was not affected. (Öhman, 2015)
Expert authors consider its therapeutic use compatible with breastfeeding. It is advisable to monitor the appearance of irritability, insomnia, poor feeding in the infant and developmental parameters (Benassayag 2024, Scoten 2024). It is contraindicated by some authors. (Ornoy 2018)
Its use as an illegal drug is totally discouraged. (Oei, 2012).
To minimize the risk, after the last recreational use of amphetamine, it is advisable to wait 55 hours (5 T ½, which eliminates 97% of the substance) before resuming breastfeeding. In the meantime, to maintain production, milk should be expressed and discarded from the breast on a regular basis.
See below the information of these related products: